Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,260.00 Price Target at Royal Bank of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by Royal Bank of Canada from $1,252.00 to $1,260.00 in a research report released on Friday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other reports. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an overweight rating in a report on Friday, August 23rd. Barclays upped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed a neutral rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Truist Financial reissued a buy rating and set a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an overweight rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and an average target price of $1,119.00.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $996.05 on Friday. The business’s 50-day moving average price is $1,125.65 and its 200 day moving average price is $1,037.99. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a market capitalization of $109.80 billion, a PE ratio of 29.40, a price-to-earnings-growth ratio of 3.55 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period in the prior year, the firm posted $8.79 EPS. The company’s revenue was up 12.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,033 shares of company stock worth $9,399,345 over the last ninety days. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. West Paces Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.